Phoenix, AZ Clinical Trials Report — July 2026

Phoenix participants should act promptly if they are considering a study that fits their condition: 39 recruiting trials are projected to close within the next 90 days, including 2 that accept healthy volunteers. Phoenix currently has 847 recruiting trials across 416 research facilities, so contacting a site early may provide more options before enrollment targets are reached.

Closing windows for Phoenix participants

The conditions most represented among trials closing soon are heart failure, major depressive disorder, and autism spectrum disorder. Other closing studies involve anxiety, chemotherapy-related nerve pain, basal cell carcinoma, atopic dermatitis, and catheter infection.

• Heart failure (2 trials)
• Major depressive disorder (2 trials)
• Autism spectrum disorder (2 trials)
• Anxiety (1 trial)
• Chemotherapy-induced pain or neuropathy (3 trials across related categories)
• Basal cell carcinoma (1 trial)
• Atopic dermatitis (1 trial)
• Catheter infection (1 trial)

There are 57 recruiting trials in Phoenix that accept healthy volunteers overall, but only two of the studies closing within 90 days are in that category. People who may qualify for a closing study should review the screening requirements and contact the research site now rather than waiting for the projected deadline.

New Phase 2 and Phase 3 opportunities

Phoenix opened 9 new trials in July, down from 19 in May. The six-month pattern shows new openings at 23 in February, 17 in March, 16 in April, 14 in May, 19 in June, and 9 in July. Four July studies are drug trials, while three are behavioral studies, one is a device study, and one is a diagnostic test.

Several new studies stand out for their late-stage development or large planned enrollment:

• NCT07700979 is Akeso’s Phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy with or without nivolumab for previously untreated, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. The study plans to enroll 900 participants.
• NCT07684820 is a Phase 2 Expedition Therapeutics study evaluating EXPD-101/FXS7553 against placebo in people with chronic obstructive pulmonary disease over 52 weeks. Planned enrollment is 600 participants.
• NCT07682896 is a Phase 2 study sponsored by Yarrow Bioscience evaluating YB-101 for safety, tolerability, pharmacokinetics, and effects on thyroid function in people with Graves’ disease. It plans to enroll 232 participants.
• NCT07714252, sponsored by the VA Office of Research and Development, evaluates a virtual nurse and social worker palliative-care team for Veterans with heart failure or COPD. The study plans to include 420 participants.
• NCT07727746 is an Arizona State University pilot studying how schools and grocery stores can promote fruit and vegetable consumption among children and families. Planned enrollment is 880 participants.
• NCT07680868 is Caris Science’s data-collection study for people receiving the Caris Chromoseq assay for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Planned enrollment is 300 participants.

New July conditions also include caregiver nutrition, interstitial lung disease, heart failure, and several studies focused on fruit and vegetable selection or consumption. Six new studies are industry-sponsored, two are classified as other, and one is federally sponsored. Sponsors opening studies locally include Akeso, Arizona State University, Caris Science, Expedition Therapeutics, Imbed Biosciences, Opus Genetics, Phoenix Children’s Hospital, and the VA Office of Research and Development.

Where Phoenix research is concentrated

Phoenix’s largest research presence is at children’s hospitals, cancer centers, Mayo Clinic locations, and neurological institutes. Phoenix Children’s Hospital leads the local list, while Cancer Center at Saint Joseph’s and Mayo Clinic Hospital in Arizona provide substantial oncology and specialty-research capacity.

• Phoenix Children’s Hospital (62 trials)
• Cancer Center at Saint Joseph’s (49 trials)
• Mayo Clinic Hospital in Arizona (47 trials)
• Mayo Clinic Arizona (37 trials)
• Research Site (36 trials)
• Phoenix Childrens Hospital (33 trials)
• Mayo Clinic (33 trials)
• Barrow Neurological Institute (23 trials)
• Mayo Clinic Hospital (22 trials)
• St. Joseph’s Hospital and Medical Center (15 trials)
• Arizona State University (12 trials)
• Banner University Medical Center (11 trials)

The two Phoenix Children’s Hospital listings together represent a particularly large concentration of pediatric research, while the Mayo and Saint Joseph’s locations offer access to cancer, neurological, cardiovascular, pulmonary, and other specialty studies. Site names can appear in more than one listing, so prospective participants should confirm the exact location and study team when making contact.

Eligibility and options outside Phoenix

Two of July’s nine new trials include children, and eight include older adults. No new trial is limited exclusively to women or men. Healthy volunteers are eligible for one of the nine new studies, while many condition-specific trials require a diagnosis, prior treatment history, or other medical criteria.

Participants willing to travel can also search nearby Arizona communities. Tucson has 7 recruiting trials, followed by Scottsdale with 6 and Gilbert with 4. Chandler has two, while Queen Creek, Flagstaff, and Sun City each have one. These locations may expand the choices available to people whose preferred Phoenix site is full or whose condition is not represented locally.

As July’s lower number of new openings suggests a tighter near-term pipeline, people with heart failure, depression, autism, anxiety, cancer-related pain, or the other closing-soon conditions should prioritize screening now. The active local base remains broad, and additional opportunities may emerge across Phoenix and neighboring Arizona cities as the summer research calendar moves into August.